14. February 2012 14:18
Teva UK has launched generic versions of Eisai’s Aricept (Donepezil Hydrochloride) and Aricept Evess (Donepezil Hydrochloride) for the symptomatic treatment of mild to moderately severe Alzheimer’s.
Donepezil film-coated tablets and Donepezil Orodispersible (OD) tablets are now immediately available in the company’s award-winning Teva 360 livery.
Kim Innes, Commercial Director at Teva, says the launch continues the company’s aim to help the NHS save more than £9bn each year by using generic prescriptions.
The launch of Donepezil and Donepezil Orodispersible is the third generic in as many weeks for the treatment of Alzheimer’s after Teva released Galantamine, Zeebral XL following the loss of patent protection.
“As the leading generics company in the UK we have the widest portfolio of our competitors, with over 700 product lines,” said Kim Innes. “We also have a growing presence in branded areas such as respiratory and in the hospital sector.
"We’re continuing 2012 with strong product launches and patent expiries. We’ve launched five products in six weeks, including this launch of Donepezil and Donepezil OD tablets (Galantamine, Zeebral XL, Latanoprost and Latanoprost + Timolol).”